© 1998 by Oxford University Press
Journal Of The National Cancer Institute, Vol 90, 146-149, Copyright © 1998 by Oxford University Press
J Applebaum, S Reynolds, J Knispel, R Oratz, R Shapiro and JC Bystryn
BACKGROUND: In the development of an antimelanoma vaccine, a critical
factor is the identification of antigens that induce a strong immune
response in humans and that are expressed by melanoma cells in vivo. The
aim of this study was to identify candidate antigens for such vaccine.
METHODS: Sixty-nine patients with surgically resected melanomas (American
Joint Commission on Cancer [AJCC] stage III) were immunized with a
polyvalent vaccine containing multiple melanoma antigens. Antimelanoma
antibodies generated in the patients' sera were used as probes to identify
the melanoma antigens that are immunogenic in humans and that are expressed
on the tumor tissue in vivo. Such responses were determined by an
immunoblotting assay that employed an antigen source prepared from membrane
fractions of freshly excised melanoma tissue. RESULTS AND CONCLUSIONS:
Vaccine treatment stimulated antibody responses in 35 (51%; 95% confidence
interval [CI] = 39%-63%) of 69 sequentially enrolled patients. The
antibodies were directed to one or more antigens with molecular masses of
45, 59, 68, 79, 89, 95, and/or 110 kd. The most immunogenic antigens were
p110 and p68, which induced responses in 33% (95% CI = 22%-44%) and 25%
(95% CI = 15%-35%) of patients, respectively. Both antigens were commonly
expressed on different melanomas, but they were absent on autologous normal
tissue and on an unrelated allogeneic tumor. All the above antigens are
attractive candidates for vaccine construction.
ARTICLES
Identification of melanoma antigens that are immunogenic in humans and expressed in vivo [published erratum appears in J Natl Cancer Inst 1998 Jul 1;90(13):1017]
Kaplan Cancer Center, New York University School of Medicine, New York 10016, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. C. Hsueh, E. Famatiga, S. Shu, X. Ye, and D. L. Morton Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma Ann. Surg. Oncol., October 1, 2004; 11(10): 892 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Livingston The Unfulfilled Promise of Melanoma Vaccines Clin. Cancer Res., July 1, 2001; 7(7): 1837 - 1838. [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Bystryn, A. Zeleniuch-Jacquotte, R. Oratz, R. L. Shapiro, M. N. Harris, and D. F. Roses Double-Blind Trial of a Polyvalent, Shed-Antigen, Melanoma Vaccine Clin. Cancer Res., July 1, 2001; 7(7): 1882 - 1887. [Abstract] [Full Text] [PDF]
|
|